CN1077885C - 联苯基磺酰胺基质金属蛋白酶抑制剂 - Google Patents

联苯基磺酰胺基质金属蛋白酶抑制剂 Download PDF

Info

Publication number
CN1077885C
CN1077885C CN97194719A CN97194719A CN1077885C CN 1077885 C CN1077885 C CN 1077885C CN 97194719 A CN97194719 A CN 97194719A CN 97194719 A CN97194719 A CN 97194719A CN 1077885 C CN1077885 C CN 1077885C
Authority
CN
China
Prior art keywords
compound
alkyl
sulfonylamino
acid
methylbutanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97194719A
Other languages
English (en)
Chinese (zh)
Other versions
CN1219166A (zh
Inventor
P·M·奥伯里恩
D·R·斯里斯科威克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1219166A publication Critical patent/CN1219166A/zh
Application granted granted Critical
Publication of CN1077885C publication Critical patent/CN1077885C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN97194719A 1996-05-17 1997-04-24 联苯基磺酰胺基质金属蛋白酶抑制剂 Expired - Fee Related CN1077885C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
US60/017,460 1996-05-17

Publications (2)

Publication Number Publication Date
CN1219166A CN1219166A (zh) 1999-06-09
CN1077885C true CN1077885C (zh) 2002-01-16

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194719A Expired - Fee Related CN1077885C (zh) 1996-05-17 1997-04-24 联苯基磺酰胺基质金属蛋白酶抑制剂

Country Status (22)

Country Link
EP (1) EP0901466B1 (https=)
JP (1) JP2000511175A (https=)
KR (1) KR20000011095A (https=)
CN (1) CN1077885C (https=)
AT (1) ATE207891T1 (https=)
BG (1) BG63940B1 (https=)
BR (1) BR9710841A (https=)
CA (1) CA2253342A1 (https=)
CZ (1) CZ294063B6 (https=)
DE (1) DE69707865T2 (https=)
DK (1) DK0901466T3 (https=)
EA (1) EA001561B1 (https=)
EE (1) EE03965B1 (https=)
ES (1) ES2167733T3 (https=)
IL (1) IL126832A0 (https=)
NO (1) NO312510B1 (https=)
NZ (1) NZ332711A (https=)
PL (1) PL186416B1 (https=)
PT (1) PT901466E (https=)
SK (1) SK282863B6 (https=)
WO (1) WO1997044315A1 (https=)
ZA (1) ZA974223B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501806A (ja) * 1994-06-22 1998-02-17 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
CA2264692A1 (en) * 1996-12-17 1998-06-25 Warner-Lambert Company Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
CA2297011C (en) * 1997-07-22 2007-01-30 Shionogi & Co., Ltd. Sulfonamide derivatives as therapeutic or prophylactic agent for glomerulopathy
WO1999032150A1 (en) * 1997-12-23 1999-07-01 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
RU2208609C2 (ru) * 1998-02-04 2003-07-20 Новартис Аг Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы
BR9815745A (pt) * 1998-03-17 2000-11-14 Warner Lambert Co Combinações de inibidor de metaloproteinase de matriz estatina
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
ATE227295T1 (de) * 1998-07-16 2002-11-15 Aventis Pharma Gmbh Phosphin- und phosphonsäurederivate als arzneimittel
ID30030A (id) * 1998-07-21 2001-11-01 Warner Lambert Co Pemberian serta penghambat acat dan mmp untuk pengobatan luka-luka aterosklerosis
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CN1347411A (zh) * 1999-04-19 2002-05-01 盐野义制药株式会社 含有噁二唑环的磺酰胺衍生物
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
CA2389681C (en) 1999-11-26 2010-11-02 Shionogi & Co., Ltd. Npy y5 antagonist
EP1331224A4 (en) * 2000-09-29 2004-03-17 Shionogi & Co THIAZOLE AND OXAZOLE DERIVATIVES
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
WO2005061459A1 (en) * 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides and methods for using same
MXPA06010974A (es) * 2004-03-22 2007-04-23 Southern Res Inst Inhibidores nopeptidos de metaloproteinasas de matriz.
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035276A1 (en) * 1994-06-22 1995-12-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035276A1 (en) * 1994-06-22 1995-12-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU713286B2 (en) 1999-11-25
KR20000011095A (ko) 2000-02-25
SK157798A3 (en) 1999-04-13
NZ332711A (en) 2000-06-23
NO985326D0 (no) 1998-11-16
PT901466E (pt) 2002-04-29
EA001561B1 (ru) 2001-04-23
EE03965B1 (et) 2003-02-17
PL329929A1 (en) 1999-04-26
DE69707865D1 (de) 2001-12-06
ZA974223B (en) 1997-12-10
DK0901466T3 (da) 2002-02-18
BR9710841A (pt) 1999-08-17
NO312510B1 (no) 2002-05-21
CZ366898A3 (cs) 1999-02-17
AU2680397A (en) 1997-12-09
WO1997044315A1 (en) 1997-11-27
EP0901466A1 (en) 1999-03-17
SK282863B6 (sk) 2002-12-03
CA2253342A1 (en) 1997-11-27
BG102918A (en) 1999-09-30
PL186416B1 (pl) 2004-01-30
DE69707865T2 (de) 2002-05-02
BG63940B1 (bg) 2003-07-31
ES2167733T3 (es) 2002-05-16
EP0901466B1 (en) 2001-10-31
EA199800988A1 (ru) 1999-04-29
NO985326L (no) 1999-01-14
HK1019585A1 (en) 2000-02-18
CN1219166A (zh) 1999-06-09
IL126832A0 (en) 1999-08-17
ATE207891T1 (de) 2001-11-15
CZ294063B6 (cs) 2004-09-15
EE9800397A (et) 1999-06-15
JP2000511175A (ja) 2000-08-29

Similar Documents

Publication Publication Date Title
CN1077885C (zh) 联苯基磺酰胺基质金属蛋白酶抑制剂
CN1213019C (zh) 磺酰胺和羧酰胺衍生物和含这种化合物作活性成分的药物
CN1280267C (zh) 磺酰氨基羧酸
CN1196671C (zh) 单和双取代的3－丙基－γ－氨基丁酸
CN1279673A (zh) (环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1230177A (zh) 作为基质金属蛋白酶抑制剂的β－磺酰基异羟肟酸
CN1551866A (zh) 羧酸衍生物化合物及包含这些化合物为活性成分的药物
CN1198096A (zh) 用于治疗与胶原蛋白过量产生有关的疾病的c－蛋白酶抑制剂
CN1278247A (zh) 作为基质金属蛋白酶抑制剂的β－磺酰基异羟肟酸的α－羟基、－氨基和卤代衍生物
CN1140508C (zh) 作为基质金属蛋白酶抑制剂的取代4-联苯基-4-羟基丁酸衍生物
CN1366518A (zh) 作为基质金属蛋白酶抑制剂的联苯基丁酸衍生物
CN1090282A (zh) 苯稠合羟基取代的环烷基和杂环化合物的磺酰胺衍生物
CN1835743A (zh) 用于治疗代谢紊乱的化合物
CN1033800A (zh) 茚满衍生物和其制备方法
CN1051354A (zh) 取代环烷并[b]二氢吲哚-和-吲哚磺酰胺
CN1419549A (zh) 不对称的4,6－双(芳氧基)嘧啶衍生物的制备方法
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
CN1125815C (zh) 用于合成喹啉衍生物的方法
CN1087295C (zh) 环氧琥珀酸衍生物
CN1705648A (zh) 具有ACAT抑制活性的а－苯基N－乙酰苯胺衍生物及其治疗应用
CN1097007A (zh) 制备2-亚氨基噻唑啉衍生物的方法和制备其中间产物的方法
CN1097745A (zh) 取代的哌嗪
CN87107427A (zh) 取代的氨甲基-5，6，7，8-四氢萘氧代乙酸，新的中间体产物，它们的制备过程及其作为药物的应用
CN1163472C (zh) 用于制备手性氨基酸的新方法
CN1062525A (zh) 苯基烷氨基化合物及其制造方法以及含这些化合物的药剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee